We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Evoke Pharma Draws Complete Response Letter for Diabetic Treatment
Evoke Pharma Draws Complete Response Letter for Diabetic Treatment
The FDA issued a complete response letter to Evoke Pharma for its Gimoti (metoclopramide) nasal spray for treatment of diabetic gastroparesis, a condition that delays emptying of the stomach.